A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments.
about
Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts.SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time.Enhancement of cyclophosphamide cytotoxicity in vivo by the benzamide analogue pyrazinamideThe effects of carbogen and nicotinamide on intravascular oxyhaemoglobin saturations in SCCVII and KHT murine tumours.Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined.Carbogen breathing with nicotinamide improves the oxygen status of tumours in patientsThe response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging.Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.Effects of nicotinamide and carbogen on tumour oxygenation, blood flow, energetics and blood glucose levels.Microregional blood flow in murine and human tumours assessed using laser Doppler microprobesDNA damage and repair in tumour and non-tumour tissues of mice induced by nicotinamideNicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review.Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy.Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamideComparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.Arteriolar oxygenation in tumour and subcutaneous arterioles: effects of inspired air oxygen content.Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations.Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy.Carbogen breathing in patients with glioblastoma multiforme submitted to radiotherapy. Assessment of gas exchange parameters.Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme.Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy.Short communication: the addition of carbogen and nicotinamide to a palliative fractionation schedule for locally advanced breast cancer.Augmentation in chemosensitivity of intratumor quiescent cells by combined treatment with nicotinamide and mild hyperthermia.Multi-omics "upstream analysis" of regulatory genomic regions helps identifying targets against methotrexate resistance of colon cancer.
P2860
Q32127388-31F56822-8061-41D3-91B1-212035C377BDQ35976983-1DF06A3D-421C-41A8-9B23-8FCC720DE3B6Q35977171-FE67A338-932A-45C5-9E1F-23FD94D7E088Q35978187-C4C5E0C5-D13D-4E19-B7DB-CE8CFEB752A3Q36080887-7084C6C1-B597-4A36-A3F2-304781E4B8FDQ36081011-B7F6E4CB-58B5-4450-97C6-E5C8236D9561Q36081866-7F35AA90-7B78-4B94-80DF-8D1286D1191AQ36420055-9EB86DE5-218C-4CB2-ADAF-E494CD498DB7Q36422762-7F7636EA-85D8-4910-81BA-F744F76363A0Q36620994-7B29F7D7-114E-4B32-B393-80E1C4DB3297Q36814458-2F450A27-6BB0-4332-8D24-6738B3C58CD0Q39997202-9D6684C5-7658-4528-B8CA-B9DAA83A76D8Q40405347-82AB31BC-63E8-49D3-8357-FCE96139C349Q40486205-3D580398-8FBC-4259-A9B7-2E5023121230Q40935433-12B017D7-8E1B-4242-929A-F0D35E7B64AFQ40941945-D74CE2B2-9DC0-41AF-B402-8425ABCE6068Q42282689-8C36CD69-4B69-4195-B2A1-5AD476160EABQ42389681-BFE32C29-1206-433A-9F9F-AD6284B3573FQ45855291-C11D5D44-6FDE-4987-BC3F-77DF4C154DC0Q48217801-A66BBFAB-E535-4027-B00E-6B18F1421198Q50750502-E553E0FA-3D6B-44F0-9A7F-DB0F3E53B282Q51583973-7D801F1D-6CCA-4674-BF73-13BB109A1771Q54182174-868D0D8B-4EAE-4387-BE93-C6B70A84D13EQ55036865-0145428D-85E0-45D7-B088-CE99EF71D372Q55383237-3CCCA459-8384-4D8A-9AC7-9FF90C090B0F
P2860
A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1991
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A therapeutic benefit from com ...... fractionated X-ray treatments.
@en
A therapeutic benefit from com ...... fractionated X-ray treatments.
@nl
type
label
A therapeutic benefit from com ...... fractionated X-ray treatments.
@en
A therapeutic benefit from com ...... fractionated X-ray treatments.
@nl
prefLabel
A therapeutic benefit from com ...... fractionated X-ray treatments.
@en
A therapeutic benefit from com ...... fractionated X-ray treatments.
@nl
P2093
P1476
A therapeutic benefit from com ...... fractionated X-ray treatments.
@en
P2093
P356
10.1016/0167-8140(91)90002-X
P577
1991-10-01T00:00:00Z